Sangamo Therapeutics (SGMO) Stock Price, Quote & News

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 970 6000

Website: www.sangamo.com

Address:

501 Canal Blvd, Richmond, United States

Wischmop Apr. 9 at 11:56 AM

$SGMO "I was just quoting, no interpretation intended. Still, the real question remains: in what way are the shareholders actually being considered here? I just don't see But then again... maybe that omission is already the answer."

0 · Reply

Chipoo Apr. 9 at 10:22 AM

$SGMO Corporate Presentation Slide 48 "We are in business development negotiations with a potential collaboration partner to commercialize the Hemophilia A program" They seem more definite on HemA than Fabry which makes no sense to me.

0 · Reply

Wischmop Apr. 9 at 9:50 AM

$SGMO "Since you clearly have a direct line to Sandy, why don't you ask him the real question next time you two chat: alongside finding a 'good solution for the company' and his touching concern for his employees' family finances, does he actually still have the interests of the shareholders in mind? Because conveniently, we were left completely off the table in his response."

2 · Reply

dongknotts Apr. 9 at 12:37 AM

$SGMO Does anyone know which institutional holders will have to sell when this goes OTC and how many shares they hold?

0 · Reply

bananastand1203 Apr. 8 at 10:52 PM

$SGMO I’m seeing on X that Evercore is the IB. Where is there support for that?

3 · Reply

lossaversion Apr. 8 at 9:03 PM

$SGMO no form 4 from natalie?

3 · Reply

Patrick2343 Apr. 8 at 7:40 PM

$SGMO Key Jerry to George Negotiation Quotes: "You know, the basic idea of negotiation as I understand it is to get your price to go up Sandy is george. If they want any sort of deal they need and outside firm to do and get sandy the heck out of the way. He said have zero say a this point.

0 · Reply

JimiJoJeeter Apr. 8 at 7:11 PM

$SGMO Just remember, in and around the Kite Pharma (Gilead) deal on February 22, 2018, this was a multi-billion dollar company with a moderate float and >$20 per share.... To see this go from such promise to a such failure is an absolute tragedy. And, it's ALL macStooges fault. He can blame the "others" all day, but not having a plan for those inevitable "others" occurrences is poor planning. Period. End-of-story!

2 · Reply

Patrick2343 Apr. 8 at 6:33 PM

$SGMO Man for a stock not to go up on a market day like today it has to pretty bad. Sandy strikes again.

1 · Reply

bananastand1203 Apr. 8 at 5:10 PM

$SGMO nothing surprising, but confirms what we all suspected

4 · Reply

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Mar 19, 2026, 4:03 PM EDT - 20 days ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Mar 9, 2026, 8:05 AM EDT - 4 weeks ago

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Feb 3, 2026, 4:05 PM EST - 2 months ago

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

Feb 3, 2026, 9:10 AM EST - 2 months ago

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

Dec 18, 2025, 8:05 AM EST - 3 months ago

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Dec 2, 2025, 8:05 AM EST - 4 months ago

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Nov 21, 2025, 8:05 AM EST - 4 months ago

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Nov 6, 2025, 8:01 AM EST - 5 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Oct 30, 2025, 4:01 PM EDT - 5 months ago

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Sep 4, 2025, 8:05 AM EDT - 7 months ago

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Aug 7, 2025, 4:01 PM EDT - 8 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 31, 2025, 4:05 PM EDT - 8 months ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jun 24, 2025, 8:05 AM EDT - 10 months ago

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

May 12, 2025, 6:26 PM EDT - 11 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025, 6:23 PM EDT - 11 months ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025, 4:00 PM EDT - 11 months ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 6, 2025, 4:35 PM EDT - 1 year ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 8:30 AM EDT - 1 year ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Apr 28, 2025, 4:31 PM EDT - 1 year ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 3, 2025, 4:01 PM EDT - 1 year ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 1 year ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Feb 6, 2025, 8:05 AM EST - 1 year ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Jan 15, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 14, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 1 year ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 10, 2025, 10:00 AM EST - 1 year ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 8, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 7, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 6, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 5, 2025, 10:00 AM EST - 1 year ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Wischmop Apr. 9 at 11:56 AM

0 · Reply

Chipoo Apr. 9 at 10:22 AM

0 · Reply

Wischmop Apr. 9 at 9:50 AM

2 · Reply

dongknotts Apr. 9 at 12:37 AM

$SGMO Does anyone know which institutional holders will have to sell when this goes OTC and how many shares they hold?

0 · Reply

bananastand1203 Apr. 8 at 10:52 PM

$SGMO I’m seeing on X that Evercore is the IB. Where is there support for that?

3 · Reply

lossaversion Apr. 8 at 9:03 PM

$SGMO no form 4 from natalie?

3 · Reply

Patrick2343 Apr. 8 at 7:40 PM

0 · Reply

JimiJoJeeter Apr. 8 at 7:11 PM

2 · Reply

Patrick2343 Apr. 8 at 6:33 PM

$SGMO Man for a stock not to go up on a market day like today it has to pretty bad. Sandy strikes again.

1 · Reply

bananastand1203 Apr. 8 at 5:10 PM

$SGMO nothing surprising, but confirms what we all suspected

4 · Reply

Rodmon77 Apr. 8 at 3:22 PM

$SGMO Accurate Chain of Insider Events Recent

1 · Reply

JimiJoJeeter Apr. 8 at 2:51 PM

$SGMO I guess only 2 tenths of a penny! 🤣😂🤣😂🤣😂🤣

0 · Reply

Scooter0732 Apr. 8 at 2:19 PM

$SGMO Royalty Co that would buy a 6% royalty on ST-920 for 75-100mm? One would think they could find that. It's odd...

0 · Reply

bananastand1203 Apr. 8 at 1:59 PM

$SGMO Also another high paying IT position posted on Sangamo website

1 · Reply

bananastand1203 Apr. 8 at 1:41 PM

$SGMO head of FP&A left

2 · Reply

Estimize Apr. 8 at 1:03 PM

Wall St is expecting -0.06 EPS for $SGMO Q1 [Reporting 05/18 AMC] http://www.estimize.com/intro/sgmo?chart=historical&metric_name=eps&utm_c

0 · Reply

Ali100_A Apr. 8 at 12:02 PM

$SGMO With Gilead agreeing to acquire Tubilus for $5BN, surely there must be some takers for acquiring $SGMO for $2BN

2 · Reply

JimiJoJeeter Apr. 8 at 11:42 AM

$SGMO We get a penny or two recovery today out of the ceasefire rally....

1 · Reply

Ali100_A Apr. 8 at 11:39 AM

$SGMO Sandy get the BO over the finish line. It’s the only option for patients and investors. And stop farting around with all the deep discussions. Nobody gives a damn.

1 · Reply

jlemx Apr. 8 at 11:02 AM

$SGMO And yet it would be enough for something to leak out, to escape the uncertainty.

2 · Reply

kiwiSurfer Apr. 8 at 12:51 AM

$SGMO Can anyone offer a real future projection?

3 · Reply

JGHersh Apr. 7 at 11:19 PM

$SGMO the comments here make me want to throw up. Idiocy at its fucking best

2 · Reply

Market Cap	106.10M
Revenue (ttm)	39.55M
Net Income (ttm)	-122.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-310.82%
Debt to Equity Ratio	0.00

Volume	5,523,500
Avg Vol	7,348,160
Day's Range	N/A - N/A
Shares Out	414.27M
Stochastic %K	30%
Beta	1.49
Analysts	Sell
Price Target	$3.20